Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure

Velásquez, Sonia Y.; Süsal, Caner; Opelz, Gerhard; García, Luis F.; Álvarez, Cristiam M.

doi:10.1016/j.humimm.2012.08.015

Cited by 9 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated sCD30 may indicate an increased immunological capacity to react against foreign HLA antigens. Due to contact with bioincompatible dialysis membranes and exposure to HLA or HLA-cross-reactive infectious agents ( D'Orsogna et al, 2011 ), end-stage renal disease patients exhibit alterations in their immune response, including increased numbers of interferon (INF)-γ-producing HLA-cross-reactive memory T -cells, reduced numbers of regulatory T -cells, augmented in vitro expansion of T -cells expressing CD30, and an increased serum sCD30 content ( Susal et al, 2002 , Velásquez et al, 2012 ). Our group reported that cytomegalovirus infection can lead to an increase of serum sCD30 levels in transplant patients ( Weimer et al, 2006 ).…”

Section: Discussionmentioning

confidence: 99%

Donor-specific antibodies require preactivated immune system to harm renal transplant

et al. 2016

Self Cite

View full text Add to dashboard Cite

HighlightsPretransplant DSA have a deleterious impact on graft survival only in the presence of high pretransplant serum levels of sCD30.The majority of patients with pretransplant DSA might be transplanted safely without special pretreatment measures.Kidney transplantation in the presence of donor-specific HLA antibodies (DSA) is associated with a high failure rate due to antibody-mediated rejection. Many centers avoid transplantations if DSA are present. Others perform such transplantations after removal of DSA by apheresis under potent immunosuppression.We provide strong evidence that DSA positive recipients reject their grafts at a high rate only if the immune activation marker sCD30 is also high, suggesting that T-cell help from an activated immune system is necessary for pretransplant DSA to exert a deleterious effect on the graft.High-risk patients with DSA and sCD30 may benefit from special treatment measures. The presence of DSA alone may not be deleterious.

show abstract

Section: Discussionmentioning

confidence: 99%

Donor-specific antibodies require preactivated immune system to harm renal transplant

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…This marker has previously been shown to be elevated in patients with CKD [34]. Also, lower levels of sCD30 have been associated with better prognosis in kidney transplant patients [35].…”

Section: Methodsmentioning

confidence: 99%

Randomized Controlled Trial of Strain-Specific Probiotic Formulation (Renadyl) in Dialysis Patients

Ranganathan

Pechenyak

Vyas

et al. 2014

BioMed Research International

111

113

View full text Add to dashboard Cite

Background. Primary goal of this randomized, double-blind, placebo-controlled crossover study of Renadyl in end-stage renal disease patients was to assess the safety and efficacy of Renadyl measured through improvement in quality of life or reduction in levels of known uremic toxins. Secondary goal was to investigate the effects on several biomarkers of inflammation and oxidative stress. Methods. Two 2-month treatment periods separated by 2-month washout and crossover, with physical examinations, venous blood testing, and quality of life questionnaires completed at each visit. Data were analyzed with SAS V9.2. Results. 22 subjects (79%) completed the study. Observed trends were as follows (none reaching statistical significance): decline in WBC count (−0.51 × 109/L, P = 0.057) and reductions in levels of C-reactive protein (−8.61 mg/L, P = 0.071) and total indoxyl glucuronide (−0.11 mg%, P = 0.058). No statistically significant changes were observed in other uremic toxin levels or measures of QOL. Conclusions. Renadyl appeared to be safe to administer to ESRD patients on hemodialysis. Stability in QOL assessment is an encouraging result for a patient cohort in such advanced stage of kidney disease. Efficacy could not be confirmed definitively, primarily due to small sample size and low statistical power—further studies are warranted.

show abstract

“…Increased serum concentrations of sCD30 are linked to presensitization; patients with HLA antibodies and previous transplantations show higher sCD30 levels [15]. Due to contact with bioincompatible dialysis membranes, foreign HLA or HLA cross-reactive infectious agents [18], end-stage renal disease patients exhibit alterations in their immune response, including increased numbers of interferon (INF)-c-producing HLA-cross-reactive memory T-cells, reduced numbers of regulatory T-cells, augmented in vitro expansion of T-cells expressing CD30, and an increased serum sCD30 content [13,19]. We reported that cytomegalovirus infection can also lead to an increase of serum sCD30 levels in transplant patients [20] and Chan et al identified CD30-positive T-cells as the major INF-c and IL-5 cytokine-producing human T-lymphocyte subset generated in response to stimulation with alloantigens [21].…”

Section: Elevated Scd30 As a Marker Of Increased T-cell Helpmentioning

confidence: 99%

The possible critical role of T-cell help in DSA-mediated graft loss

et al. 2018

Self Cite

View full text Add to dashboard Cite

Summary In this review, we discuss a possible central role of T‐cell help in severe forms of graft damage mediated by donor‐specific HLA antibodies (DSA). Some kidney transplant recipients with pretransplant DSA show a high graft failure rate, whereas in other patients DSA do not harm the transplanted kidney and in most cases, disappear shortly after transplantation. Analyzing 80 desensitized highly immunized kidney transplant recipients and another multicenter cohort of 385 patients with pretransplant HLA antibodies, we reported recently that an ongoing T‐cell help from an activated immune system, as measured by an increased level of soluble CD30 in serum, might be necessary for the DSA to exert a deleterious effect. Patients positive for both pretransplant DSA and sCD30 appear to require special measures, such as the elimination of DSA from the circulation, potent immunosuppression, good HLA‐matching, and intense post‐transplant monitoring, whereas exclusion of DSA‐positive patients from transplantation in the absence of high sCD30 may not be justified in all cases, even if the pretransplant DSA are strong and complement‐activating.

show abstract

Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure

Cited by 9 publications

References 45 publications

Donor-specific antibodies require preactivated immune system to harm renal transplant

Donor-specific antibodies require preactivated immune system to harm renal transplant

Randomized Controlled Trial of Strain-Specific Probiotic Formulation (Renadyl) in Dialysis Patients

The possible critical role of T-cell help in DSA-mediated graft loss

Contact Info

Product

Resources

About